The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
ACVR1 R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A
Open accessAbstract
In patients with fibrodysplasia ossificans progressiva, the disease-causing mutation changes the ligand response profile of the ACVR1 receptor so that it is activated by the normally antagonistic ligand activin A.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“as ActRIIA/B receptors mediate many diverse biologic processes by responding to over a dozen ligands23–25”
From GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates (2025) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“since these receptors mediate the diverse biologic actions of more than a dozen ligands23–25, there are potential concerns with broad ActRIIA/B blockade as an approach to maintain or increase muscle growth.”
From GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates (2025) · cites this paper as [24]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new logic for DNA engineering using recombination in Escherichia coli
Zhang, Y., Buchholz, F., Muyrers, J. P. P., & Stewart, A. F. (1998) · Nature Genetics · doi:10.1038/2417 · Cited by 1,228
Shore, E. M., Xu, M., Feldman, G. J., Fenstermacher, D., Cho, T., Choi, I. H., Connor, J. M., Delai, P. L. R., Glaser, D. L., Merrer, M. F. L., et al. (2006) · Nature Genetics · doi:10.1038/ng1783 · Cited by 1,215
Wieser, R., Wrana, J. L., & Massagué, J. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07214.x · Cited by 689
BMP type I receptor inhibition reduces heterotopic ossification
Yu, P. B., Deng, D. Y., Lai, C. S. C., Hong, C. C., Cuny, G. D., Bouxsein, M., Hong, D. W., McManus, P. M., Katagiri, T., Sachidanandan, C., et al. (2008) · Nature Medicine · doi:10.1038/nm.1888 · Cited by 641
Self-citationAttisano, L. (1993) · Cell · doi:10.1016/0092-8674(93)90488-c · Cited by 639
High-throughput engineering of the mouse genome coupled with high-resolution expression analysis
Valenzuela, D. M., Murphy, A. J., Frendewey, D. A., Gale, N. W., Economides, A. N., Auerbach, W., Poueymirou, W. T., Adams, N. C., Rojas, J., Yasenchak, J., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt822 · Cited by 583
Self-citationSpecific Activation of Smad1 Signaling Pathways by the BMP7 Type I Receptor, ALK2
Macías‐Silva, M., Hoodless, P. A., Tang, S. J., Buchwald, M., & Wrana, J. L. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.40.25628 · Cited by 476
Murphy, A. J., Macdonald, L. E., Stevens, S. G., Karow, M. L., Dore, A. T., Pobursky, K. J., Huang, T. T., Poueymirou, W. T., Esau, L., Meola, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324022111 · Cited by 469
Self-citationA directional strategy for monitoring Cre-mediated recombination at the cellular level in the mouse
Schnütgen, F., Doerflinger, N., Calleja, C., Wendling, O., Chambon, P., & Ghyselinck, N. B. (2003) · Nature Biotechnology · doi:10.1038/nbt811 · Cited by 401
Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes
Macdonald, L. E., Karow, M. L., Stevens, S. G., Auerbach, W., Poueymirou, W. T., Yasenchak, J., Frendewey, D. A., Valenzuela, D. M., Giallourakis, C. C., Alt, F. W., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323896111 · Cited by 396
Self-citation
Cited by
Sorted by citations
Items 401–448 of 448
Kopylov, E. D., Антонович, Я. И., Limaev, I. S., Валерьевич, Е. А., & Deev, R. V. (2025) · Genes and Cells · doi:10.17816/gc678636
Immune Involvement in the Development and Maintenance of Oral and Craniofacial Bones
Ono, T. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-03176-1_25
Smilde, B. J., Stockklausner, C., Keen, R. W., Whittaker, A., Bullock, A. N., von Delft, A., van Schoor, N. M., Yu, P. B., & Eekhoff, E. M. W. (2022) · Figshare · doi:10.6084/m9.figshare.19959934
Self-citationGao, P., Inada, Y., Hotta, A., Sakurai, H., & Ikeya, M. (2024) · Figshare · doi:10.6084/m9.figshare.25434343
Smilde, B. J., Stockklausner, C., Keen, R. W., Whittaker, A., Bullock, A. N., von Delft, A., van Schoor, N. M., Yu, P. B., & Eekhoff, E. M. W. (2022) · Figshare · doi:10.6084/m9.figshare.19959937
Self-citationPeng, K., Karunakaran, K. D., Labadie, R., Veliu, M., Cheung, C., Lee, A., Yu, P. B., & Upadhyay, J. (2021) · Figshare · doi:10.6084/m9.figshare.13669525
Self-citationMaekawa, H., Jin, Y., Nishio, M., Kawai, S., Nagata, S., Kamakura, T., Yoshitomi, H., Niwa, A., Saito, M. K., Matsuda, S., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21185556
Additional file 7 of FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells
Quist-Løkken, I., Andersson-Rusch, C., Kastnes, M. H., Kolos, J. M., Jatzlau, J., Hella, H., Olsen, O. E., Sundan, A., Knaus, P. I., Hausch, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22616698
Gao, P., Inada, Y., Hotta, A., Sakurai, H., & Ikeya, M. (2024) · Figshare · doi:10.6084/m9.figshare.26695098
Maekawa, H., Kawai, S., Nishio, M., Nagata, S., Jin, Y., Yoshitomi, H., Matsuda, S., & Toguchida, J. (2020) · Figshare · doi:10.6084/m9.figshare.12364433
Gao, P., Inada, Y., Hotta, A., Sakurai, H., & Ikeya, M. (2024) · Figshare · doi:10.6084/m9.figshare.25434166
Additional file 1 of A therapeutic target for CKD: activin A facilitates TGFβ1 profibrotic signaling
Soomro, A., Khajehei, M., Li, R., O'Neil, K. S., Zhang, D., Gao, B., MacDonald, M. E., Kakoki, M., & Krepinsky, J. C. (2023) · Figshare · doi:10.6084/m9.figshare.22602349
Additional file 2 of FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells
Quist-Løkken, I., Andersson-Rusch, C., Kastnes, M. H., Kolos, J. M., Jatzlau, J., Hella, H., Olsen, O. E., Sundan, A., Knaus, P. I., Hausch, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22616683
Gao, P., Inada, Y., Hotta, A., Sakurai, H., & Ikeya, M. (2024) · Figshare · doi:10.6084/m9.figshare.26695095
Pignolo, R. J., Mukaddam, M. A., Baujat, G., Brown, M. A., Cunto, C. L. D., Hsiao, E. C., Keen, R. W., Sang, K. L. Q., Grogan, D. R., Marino, R., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24558154
Additional file 3 of FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells
Quist-Løkken, I., Andersson-Rusch, C., Kastnes, M. H., Kolos, J. M., Jatzlau, J., Hella, H., Olsen, O. E., Sundan, A., Knaus, P. I., Hausch, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22616686
Gao, P., Inada, Y., Hotta, A., Sakurai, H., & Ikeya, M. (2024) · Figshare · doi:10.6084/m9.figshare.26695101
Additional file 6 of FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells
Quist-Løkken, I., Andersson-Rusch, C., Kastnes, M. H., Kolos, J. M., Jatzlau, J., Hella, H., Olsen, O. E., Sundan, A., Knaus, P. I., Hausch, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22616695
Additional file 5 of FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells
Quist-Løkken, I., Andersson-Rusch, C., Kastnes, M. H., Kolos, J. M., Jatzlau, J., Hella, H., Olsen, O. E., Sundan, A., Knaus, P. I., Hausch, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22616692
Additional file 4 of FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells
Quist-Løkken, I., Andersson-Rusch, C., Kastnes, M. H., Kolos, J., Jatzlau, J., Hella, H., Olsen, O. E., Sundan, A., Knaus, P. I., Hausch, F., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22616689
Abera, S. A., Belay, S. A., Molla, Y. D., Yefter, E. T., Berhanu, M., & Worku, M. A. (2026) · International Journal of Surgery Case Reports · doi:10.1097/rc9.0000000000000075
Kim, Y., Cho, T., Kim, M.-J., Jung, E., Kim, D., Oh, N., Shin, C. H., Lee, H. R., Kim, Y., Ryoo, H., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8453923/v1
Hanson, L. R., Scalise, K. L., Esch, R. M., Nevo, L., & Goldhamer, D. J. (2026) · Bone · doi:10.1016/j.bone.2026.117829
Koirala, P., Chen, Z., Wu, M., Maridas, D. E., Siegel, A. E., Liu, C., Hanumantharao, S. N., Mishina, Y. M., Rosen, V., & Agarwal, S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.11.705403
Primary Cilia Are Required for Efficient BMP Signaling in Traumatic Heterotopic Ossification
Yuan, X., Toutounchi, S., Law, S. F., Achudhan, D., Chandra, A., He, K., Cao, Y., Hu, J., Pignolo, R. J., & Wang, H. (2026) · Biomedicines · doi:10.3390/biomedicines14030712
Fibrodysplasia ossificans progressiva
Großmann, N. Z., Rivera, L. M., Renteria, D., Kaplan, F. S., & Shore, E. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13683-2.00038-4
The transgenic Drosophila HLA-B27 : a new model for the study of spondyloarthritis
Grandon, B. (2018) · theses.fr (ABES) · doi:10.70675/e73e63dezb0b7z4e75z8393zff5ae78924a2
Inflammation et paraostéoarthropathies neurogènes
Salga, M. (2019) · theses.fr (ABES) · doi:10.70675/6b946b19zc8c3z4686z8586z667cbe37d4d0
Hilliquin, S. (2023) · theses.fr (ABES) · doi:10.70675/92584e44z94f9z451bz881czfa51ee6d24c1
Beaufrère, M. (2024) · theses.fr (ABES) · doi:10.70675/e2ad4bb8zc461z4159z99eaz2d8e71144ddf
Chen, S., & Lin, H. (2026) · Biomolecules · doi:10.3390/biom16040585
Aberrant ciliogenesis induced by enhanced BMP signaling causes heterotopic ossificationPreprint
Yamaguchi, H., Wang, J., Yan, F., Bi, J., Darabi, R., Lagor, W. R., Zhao, Z., Economides, A. N., Mishina, Y. M., & Komatsu, Y. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.02.735922
Self-citationKoirala, P., Chen, Z., Wu, M., Maridas, D. E., Siegel, A. E., Liu, C. H., Hanumantharao, S. N., Mishina, Y. M., Rosen, V., & Agarwal, S. (2026) · iScience · doi:10.1016/j.isci.2026.116602
Machine Learning‐Based Text Processing Reveals Research Trends in Heterotopic Ossification
Sun, Y., Zhu, Q., Yu, C., Wang, C., Yan, W., & Jiang, C. (2026) · Analytical Cellular Pathology · doi:10.1155/ancp/9959615
Aierxiding, S., & Ren, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1788883 · Cited by 1
Pourdadashi, A., Eskandari, P., Ghayour-Najafabadi, Z., Tajari, A., Heydarzadeh, S., & Panahi, M. (2026) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2026.109276
Papa, R., Rhee, S., Delai, P. L. R., 张克勤, Balcázar, I. B., Rethanavelu, K., Fujiwara, T., Mishima, K., Tabarkiewicz, J., Funck‐Brentano, T., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01599-0
Self-citationA novel and effective treatment for fibrodysplasia ossificans progressiva
Schipani, E. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01868-4
Activins and BMPs: The yin and yang of diffuse midline gliomas
Prasad, K., & Becher, O. J. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.09.002
Single-Cell Behavioromics Enables Fate Prediction of Individual Hematopoietic Stem CellsPreprint
Chankhunthod, A. B., Sorenson-Graff, R., Mercoli, J. I., Ishida, T., Dozono, S., Wellington, R., Fong, Y., Hadland, B., & Zhao, H. G. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.06.757119
Inhibition of CCN2/CTGF prevents heterotopic ossification in fibrodysplasia ossificans progressiva
Deber, A., Farfán, N., Ferrer-Roig, M., Moro, J., Rovira, M., Rosa, J. L., & Ventura, F. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.09.040
Cui, L., Ouyang, Q., Guo, J., Cai, W., Pang, Q., Chi, Y., Jiajue, R., Li, X., Liu, W., Jiang, Y., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1941326
BindingDB Entry 50016627: Inhibition of ALK2 with bicyclic pyridyllactams.
BindingDB (2023) · UC San Diego · doi:10.7270/q2js9vgj
Metadata
- Authors
- Hatsell, S. J., Idone, V., Wolken, D. M. A., Huang, L., Kim, H. J., Wang, L., Wen, X., Nannuru, K. C., Jimenez, J., Xie, L., Das, N., Makhoul, G., Chernomorsky, R., D’Ambrosio, D., Corpina, R. A., Schoenherr, C. J., Feeley, K., Yu, P. B., Yancopoulos, G. D., Murphy, A. J., & Economides, A. N.
- Affiliations
- Regeneron (United States) (US)
- Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA.
- Brigham and Women's Hospital (US)
- Corresponding author
- Hatsell, Sarah J.
- Idone, Vincent
- Wolken, Dana M. Alessi
- Huang, Lily
- Kim, Hyon J.
- Feeley, Kieran
- Economides, Aris N.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2015-09-02
- Volume
- 7
- Issue
- 303
- Pages
- 303ra137-303ra137
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC6164166
- OpenAlex
- W2145304853
- Cited by
- 446
- References
- 38
- Citations by year
- 2026: 26 · 2025: 27 · 2024: 49 · 2023: 41 · 2022: 33 · 2021: 47 · 2020: 52 · 2019: 39 · 2018: 34 · 2017: 54 · 2016: 34 · 2015: 10
- FWCI
- 36.97
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR057374)
- Topics
- Health Sciences › Medicine › Rheumatology › Heterotopic Ossification and Related Conditions
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Keywords
- fibrodysplasia ossificans progressiva, ACVR1 R206H mutation, activin A, heterotopic ossification, BMP signaling, conditional knock-in mice, BMP antagonism
- MeSH terms
- Animals, Mice, Transgenic, Mutation, Myositis Ossificans, Protein Binding, Tacrolimus Binding Protein 1A, Activins, Activin Receptors, Type I, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
